BREATHE-XeNCT07896902
Xenon MRI to Evaluate Changes to Lung Function Following Bronchoscopic Treatment of Air Trapping in Emphysema
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Primary Endpoint
Timeframe: 6 Months
Secondary (1)
Ventilation
Arms and interventions
XENOVIEWOther
Hyperpolarized ¹²⁹Xe (HP ¹²⁹Xe) gas (XENOVIEW, Polarean; NDA 214375), administered by inhalation as an MRI signal agent. Produced on-site immediately prior to use under site-held INDs: IND 151978 (KUMC); IND 178832 (UAB).
Drugs: Hyperpolarized Xenon MRI
Devices: Apreo BREATHE Airway Scaffold
Sites
2 sites in 1 country